C

Cabaletta Bio

67 employees

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
dermatology
autoimmune
cell therapy
Therapeutics
Medical
immunology
Robotics
biotech

Date founded

2017

Funding rounds raised

Total raised

$50M

from 6 investors over 6 rounds

C

Cabaletta Bio raised $50M on January 3, 2019

Investors: Adage Capital Management, 5AM Ventures, Redmile Group and Cormorant Capital

C

Cabaletta Bio raised $38M on November 8, 2018

Investors: Adage Capital Management and 5AM Ventures

FAQ